Why the study?
Does trastuzumab increase the risk of heart failure in patients with metastatic breast cancer?
Does trastuzumab increase the risk of heart failure in patients with metastatic breast cancer?
Answers are grounded in this paper and cite their sources.
Trastuzumab is associated with significant cardiotoxicity, particularly when combined with anthracyclines, necessitating careful risk-benefit assessment.
Trastuzumab, a monoclonal antibody against the HER2 receptor, was recently approved for the treatment of metastatic breast cancer. However, 28% of patients receiving both an anthracycline and trastuzumab developed heart failure. Although HER2 overexpression has been associated with the development of cancer, HER2 receptors seem to be cardioprotective because they mediate the activation of important cardiac survival pathways. Because the morbidity and mortality of heart failure surpasses that of many cancers, prudent medical practice mandates that physicians learn more about the mechanisms of trastuzumab-induced cardiotoxicity and develop algorithms for assessing risk/benefit ratios before extending the use of this agent to patients with less invasive forms of breast cancer.
No takes yet. Share an insight, caveat, or question.
Feldman et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: